Home Start
Lecture
Presentation 		Download
Podcast		 Enter
Learning Assessment
& Evaluation Form 		Download
Activity
Workbook

OVERVIEW
This free activity consists of a lecture presentation, a learning assessment, and an evaluation form.
The content of this virtual lecture is derived from a live educational webcast presented on Thursday, June 10, 2010.

MEDIUM: Virtual Lecture
INTERNET RELEASE DATE: July 22, 2010
(Continuing education credit is no longer available for this activity.)

Estimated time to complete this activity: 1.75 hours

TARGET AUDIENCE
This activity is designed to meet the educational needs of primary care physicians, nurses, social workers and other healthcare professionals involved in the management of patients with blood cancers.

ACTIVITY PURPOSE
This activity is intended to inform healthcare professionals about monitoring and managing long- and late-term effects of treatment for blood cancer survivors.

STATEMENT OF NEED
Advances in improved diagnostic methods and treatment of hematologic malignancies have led to an increased number of cancer survivors. Although most therapeutic modalities for cancer are beneficial and life-saving, long-term or late adverse sequelae are increasingly prevalent, serious, and persistent in survivors of pediatric and adult cancers.1 A thorough review of a patient’s medical history, treatments, and co-morbid conditions is necessary for the primary care physician to recognize late effects of therapy and pursue appropriate interventions.2 Limited studies effectively associate treatment exposures with future consequences; however, through the grading of late effects, appropriate surveillance and treatment interventions may be implemented.3 Blood cancer survivors should be evaluated for cancer recurrence during follow-up visits with primary care providers (PCPs). Effective monitoring begins with PCP awareness of disease-specific signs and symptoms and includes thorough patient history and examination, along with appropriate use of laboratory tests and diagnostic procedures.

1Aziz NM. Acta Oncol. 2007;46:417-432.
2Ganz PA. Prim Care Clin Office Pract. 2009;36:721-741.
3Aziz NM. "Late Effects of Cancer Treatments." In: Cancer Survivorship. New York: Springer New York; 2007:54-76.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

  • Describe the role of primary care practitioners in caring for cancer survivors
  • Describe the long-term and late effects associated with treatments for blood cancers
  • Identify clinical trials evidence for late effects of treatments and survivorship in blood cancers
  • Identify signs or symptoms that suggest the need for increased observation, testing and/or referral for possible recurrence or other morbidity in blood cancer survivors
  • List the screening tests and optimal schedule for monitoring of blood cancer survivors for routine cancer prevention and detection of long- and late-term effects of treatment

FACULTY

Robert J. Arceci, MD, PhD
King Fahd Professor of Pediatric Oncology
Professor of Pediatrics and Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Baltimore, MD



Judith E. Karp, MD
Professor of Oncology and Medicine
Director, Leukemia Program
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Baltimore, MD


PHYSICIAN CONTINUING EDUCATION INFORMATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Robert Michael Educational Institute LLC (RMEI). PIM is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANT & NURSE PRACTITIONER CONTINUING EDUCATION INFORMATION
Physician assistants and nurse practitioners should contact their respective licensure and certification bodies for information on use/conversion of AMA PRA Category 1 Credit(s)™.

NURSE AND SOCIAL WORKER CONTINUING EDUCATION INFORMATION
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.75 continuing education contact hours through the California Board of Registered Nursing. The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/2008–12/2011. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.75 CE clinical clock hours.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studied utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Dr. Robert J. Arceci has no affiliations with commercial interests to disclose.
  • Dr. Judith E. Karp has no affiliations with commercial interests to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Robert Michael Educational Institute LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Laura Altobelli, MS, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine

  • Jan Hixon, RN, BSN, MA, has no affiliations with commercial interests to disclose.
  • Trace Hutchison, PharmD, has no affiliations with commercial interests to disclose.
  • Julia Kimball, RN, BSN, has no affiliations with commercial interests to disclose.
  • Samantha Mattiocci, PharmD, has no affiliations with commercial interests to disclose.
  • Jan Schultz, RN, MSN, CCMEP, has no affiliations with commercial interests to disclose.
  • Patricia Staples, MSN, NP-C, CCRN, has no affiliations with commercial interests to disclose.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME credit for this activity. During the period July 22, 2010, through July 22, 2011, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-Test/Evaluation by Course" and search by course ID 7312. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Robert Michael Educational Institute LLC (RMEI), The Leukemia & Lymphoma Society (LLS), Genentech and Biogen Idec do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Robert Michael Educational Institute LLC (RMEI), The Leukemia & Lymphoma Society (LLS), Genentech and Biogen Idec. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

SUPPORT STATEMENT
This activity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine, and is supported by an educational grant from Genentech/Biogen Idec.

FEE INFORMATION
There is no fee for this educational activity.

QUESTIONS AND TECHNICAL ASSISTANCE
For questions regarding the content of this activity, contact the Information Resource Center (IRC) at 800-955-4572, or visit the LLS website at www.LLS.org. For technical assistance, contact jungsen@rmcom.net.

SYSTEM REQUIREMENTS
Hardware/Software requirements include:
• Windows 95, 98se, ME, XP, NT 4.0, 2000   
  - Internet Explorer 4.0+
  - Netscape Navigator 6.2+
  - Mozilla Firefox 1.0+
• Macintosh 9.2, OS X 10.1+
  - Safari 1.1+
  - Netscape Navigator 6.2+
  - Internet Explorer 5.2+
  - Mozilla Firefox 1.0+
• Additional Requirements
  - Windows Media Player
  - Internal/external speakers
  - Broadband connection (DSL/cable) recommended

 

 

RMEI Privacy Statement

Questions, grievances, assistance for people with disabilities or for more information on LLS programs, please contact the LLS Information Resource Center (IRC) at (800) 955-4572.